Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03317899 · OUTCOME

Median Number of Days of Febrile Neutropenia During the Auto HSCT Inpatient Stay

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma · Source last updated 2025-12-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days of inpatient febrile neutropenia
Interval / dispersion
Full Range
Time frame
Up to 60 days

What was measured

Will be summarized by treatment arm and compared using Wilcoxon rank sum tests.

Groups in this outcome

Group I (auto HSCT tbo-filgrastim)

Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days. Hematopoietic Cell Transplantation: Undergo auto HSCT Tbo-filgrastim: Given subcutaneously Laboratory Biomarker Analysis: Correlative Studies

Group II (auto HSCT)

Patients undergo auto Hematopoietic Cell Transplantation (HSCT). Hematopoietic Cell Transplantation: Undergo auto HSCT Laboratory Biomarker Analysis: Correlative Studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group I (auto HSCT tbo-filgrastim)38
Group II (auto HSCT)39

Reported measurements

Source class 1
Values in days of inpatient febrile neutropenia · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Group I (auto HSCT tbo-filgrastim)2Not reported06Not reported
Group II (auto HSCT)4Not reported19Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    OTHER
    p Value
    0.001
    statistical Method
    Wilcoxon (Mann-Whitney)
Complete source fields
analyses
  1. group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    OTHER
    p Value
    0.001
    statistical Method
    Wilcoxon (Mann-Whitney)
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        6
        value
        2
      2. group Id
        OG001
        lower Limit
        1
        upper Limit
        9
        value
        4
denoms
  1. counts
    1. group Id
      OG000
      value
      38
    2. group Id
      OG001
      value
      39
    units
    Participants
description
Will be summarized by treatment arm and compared using Wilcoxon rank sum tests.
dispersion Type
Full Range
groups
  1. description
    Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days. Hematopoietic Cell Transplantation: Undergo auto HSCT Tbo-filgrastim: Given subcutaneously Laboratory Biomarker Analysis: Correlative Studies
    id
    OG000
    title
    Group I (auto HSCT tbo-filgrastim)
  2. description
    Patients undergo auto Hematopoietic Cell Transplantation (HSCT). Hematopoietic Cell Transplantation: Undergo auto HSCT Laboratory Biomarker Analysis: Correlative Studies
    id
    OG001
    title
    Group II (auto HSCT)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 60 days
title
Median Number of Days of Febrile Neutropenia During the Auto HSCT Inpatient Stay
type
SECONDARY
unit Of Measure
days of inpatient febrile neutropenia

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice